Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Therapeutics|January 22, 2023
Multidrug Interactions: Why Do They Occur and How to Handle?Pamela Dow, Veronique Michaud, Jacques Turgeon
American Journal of Translational Research|January 17, 2022
Illustrative and historic cases of phenoconversionVeronique Michaud, Pamela Dow, Jacques Turgeon
The American Journal of Managed Care|June 23, 2022
Revisiting conclusions on the empiric segmentation of high-risk patientsVeronique Michaud, Pamela Dow, Jacques Turgeon
Journal of Clinical Pharmacology|August 12, 2021
Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive InhibitionTao Long, Rodrigo Cristofoletti, Brian Cicali, et al.
Journal of Clinical Medicine|July 9, 2020
ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS SystemVeronique Michaud, Malavika Deodhar, Meghan Arwood, et al.
International Journal of Molecular Sciences|April 30, 2021
Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier LevelSweilem B Al Rihani, Lucy I Darakjian, Malavika Deodhar, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Pre-Emptive Drug Safety Evaluation of Iclepertin (BI-425809) Using Real-World Data and Virtual Addition of This Medication to the Actual Drug Regimen of Individuals from Large PopulationsSebastian Härtter, Veronique Michaud, Matt K Smith, et al.
Clinical and Translational Science|September 5, 2020
Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed DrugsVeronique Michaud, Pamela Dow, Sweilem B Al Rihani, et al.
Journal of Clinical Medicine|August 14, 2020
Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with PolypharmacySweilem B Al Rihani, Matt K Smith, Ravil Bikmetov, et al.
Pharmaceutics|September 9, 2020
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical PracticeMalavika Deodhar, Sweilem B Al Rihani, Meghan J Arwood, et al.
Pageof 2